A senolytics trial in human idiopathic pulmonary fibrosis patients selectively ablating senescent cells using Dasatinib and Quercetin (DQ) alleviates physical dysfunction and circulating SASP factors which have been confirmed in a cohort of inflammatory disease.

Our data provide a rationale for trials of such anti-ageing drugs in patients with arthralgia at risk of developing RA which can be validated in future preclinical and clinical studies to explore dosing and treatment duration to delineate the therapeutic window and maximise therapeutic benefits of proposed geroprotective drugs.